Loading...
Loading...
- MorphoSys AG MOR expects group revenues of €155 million to €180 million (previously: €150 to € 200 million, provided on March 15 and reiterated on May 5, 2021).
- The updated revenue guidance primarily reflects updated Monjuvi product sales expectations.
- MorphoSys now expects operating expenses of €435 million to € 465 million (previously €355 to € 385million).
- R&D expenses now are expected to comprise 52 to 57% of Group operating expenses (previously 45-50%), excluding one-time transaction-related costs.
- The updated guidance for operating expenses mainly reflects the acquisition of Constellation Pharmaceuticals.
- The revised numbers also include one-time transaction costs of €36 million.
- As a result of the updated Monjuvi product sales expectations, the balance sheet position "financial liabilities from collaborations, net of current portion" is reduced from €547.6 million to €445.9 million.
- Full results will be published as planned on July 28.
- Price Action: MOR shares are down 5% at $15.37 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in